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Abstract
Introduction:  Information  on  host  factors  that  contribute  to  false  negative  and  indeterminate
results in  interferon-  release  assays  (IGRA)  are  critical  to  improve  the  usefulness  of  these  tests
in the  fight  against  tuberculosis  (TB)  epidemics.
The  aim  of  this  study  was  to  estimate  and  compare  the  sensitivity  of  an  IGRA  and  the  tuber-
culin skin  test  (TST),  independently  and  as  a  combined  approach,  in  patients  with  TB  and  to
identify risk  factors  associated  with  false  negative  and  indeterminate  IGRA  results.
Methods:  Retrospective  cohort  study  of  all  active  TB  notifications  with  an  IGRA  result  (n  =  1230),
from 2008  to  2015.  68.0  %  (n  =  727)  of  these  patients  had  a  TST  result  interpreted  using  a  5  mm
(TST-5 mm)  and  10  mm  (TST-10  mm)  cutoff.  Sensitivity  was  determined  for  both  tests.
Logistic  regression  analysis  was  used  to  evaluate  the  association  of  sociodemographic  and
clinical factors  to  the  risk  of  false  negative  or  indeterminate  IGRA  results.
Results:  IGRA,  TST-5  mm  and  TST-10  mm  were  positive  in  82.4  %,  84.5  %  and  78.4  %  of  the
patients  that  performed  both  tests.  When  used  combined,  IGRA/TST-5  mm  sensitivity  was  91.7
% and  IGRA/TST-10  mm  sensitivity  was  90.6  %.  Age≥65  years,  alcohol  abuse  and  pulmonary  TB
were predictive  factors  for  indeterminate  results.  Inflammatory  diseases  and  pulmonary  TB
were statistically  associated  with  false  negative  IGRA  results.Please  cite  this  article  in  press  as:  Santos  JA,  et  al.  Pulmonol.  2019.  https://doi.org/10.1016/j.pulmoe.2019.11.001
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Conclusion:  Inflammatory  diseases  and  pulmonary  TB  were  identified  as  factors  for  false  neg-
ative IGRA  results.  Our  results  indicate  that  the  use  of  both  tests  in  a  combined  approach,
especially  in  specific  risk  groups  of  the  population,  could  increase  the  sensitivity  of  the  screening
process and  accelerate  the  achievement  of  the  WHO  End  TB  Strategy  goals.
© 2019  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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he  timely  identification  of  latent  tuberculosis  infection
LTBI)  cases  and  implementation  of  preventive  treatment
an  substantially  decrease  the  risk  of  people  developing
uberculosis  (TB)  disease  from  a  latent  infection  and,  conse-
uently,  reduce  TB-related  morbidity  and  mortality,  reduce
ransmission,  and  the  burden  of  the  disease.1
The  existing  screening  tests  are  indirect  methods  that
nly  provide  immunological  evidence  of  host  sensitization  to
ycobacterium  tuberculosis  antigens,  do  not  differentiate
ccurately  between  LTBI  and  active  TB  or  provide  evidence
egarding  the  stage  and  potential  progression  from  infection
o  disease.2
WHO  guidelines  recommend  the  use  of  the  tuberculin
kin  test  (TST)  and  the  interferon- release  assays  (IGRA)
s  screening  tests.
IGRAs  measure  T-cell  release  of  interferon- in  response
o  stimulation  by  two  strongly  immunogenic  but  highly
pecific  M.  tuberculosis  complex  antigens  (ESAT-6  and  CFP-
0).  Two  IGRAs  are  commercially  available,  QuantiFERON-TB
old  assay  (Qiagen)  and  the  T-SPOT.TB  assay  (Oxford
mmunotec),  both  detecting  the  release  of  interferon- in
esponse  to  the  specific  M.  tuberculosis  antigens  through
ifferent  methods.
IGRAs  have  higher  specificity  for  M.  tuberculosis  than  the
ST,  as  the  antigens  used  are  not  encoded  in  the  genomes
f  any  of  the  BCG  vaccine  strains  or  most  species  of  non-
uberculous  mycobacteria.3 Furthermore,  these  tests  have
ogistic  advantages  when  compared  to  TST  (e.g.  require  only
ne  visit),  have  positive  and  negative  controls  (e.g.  identi-
cation  of  potential  cases  of  anergy),  and  no  boost  effect
hen  repeated.2
However,  these  assays  are  more  expensive  and  require
aboratory  infrastructure.  Also,  T-cell  assays  such  as  IGRA
re  susceptible  to  variability  by  different  factors  at  mul-
iple  levels,  including  assay  manufacturing,  preanalytical
rocessing  (e.g.  blood  volume,  sample  transport  tempera-
ure,  incubation  time)  or  analytical  testing.3
IGRAs  have  shown  reduced  sensitivity  in  immunocompro-
ised  patients,  especially  in  those  with  a  severe  immune
epression,  such  as  patients  with  diabetes4 or  HIV  infection.5
GRAs  have  also  presented  a  lower  sensitivity  in  young
<5years  of  age)  or  immunocompromised  children.6,7
Another  drawback  of  IGRA  testing  is  the  occurrence  of
ndeterminate  results,  which  may  result  from  an  insufficient
mmune  response  to  the  positive  control  or  a  high  level  ofPlease  cite  this  article  in  press  as:  Santos  JA,  et  al.  Pulmonol.  
esponse  in  the  negative  control,8 with  previous  studies  pre-
enting  rates  of  indeterminate  IGRA  results  ranging  between
 %  and  11  %.8
i
d
sIn  order  to  improve  the  usefulness  of  the  IGRAs  as  a  diag-
ostic  aid  for  detection  of  LTBI,  it  is  essential  to  better
nderstand  which  factors  are  associated  with  false  negative
nd  indeterminate  IGRA  results.
Since  there  is  no  diagnostic  gold  standard  for  LTBI  to  help
valuate  the  IGRAs,  sensitivity  can  be  estimated  using  surro-
ate  reference  standards  such  as  IGRA  results  from  patients
ith  a  definitive  TB  diagnosis  and,  through  collected  epi-
emiological  data,  determine  factors  that  may  be  associated
ith  false  negative  results.
The  objective  of  this  study  was  to  analyse  the  perfor-
ance  of  an  IGRA  test  in  patients  with  active  TB.  The  specific
bjectives  were  to:  (i)  determine  and  compare  the  sensitiv-
ty  of  IGRA  and  TST  tests;  (ii)  search  for  risk  factors  that
ould  be  linked  with  indeterminate  IGRA  results;  and  (iii)
scertain  risk  factors  that  could  be  associated  with  false
egative  IGRA  results.
aterial and methods
tudy  design  and  data  source
etrospective  cohort  study  centered  on  data  from  active
B  cases  notified  in  the  Portuguese  National  Tuberculosis
urveillance  System  (SVIG-TB),  from  2008  to  2015.  This  offi-
ial  database  is  generated  by  direct  compulsory  reporting  by
ealth  care  providers  and  the  data  from  this  official  system
f  notification  is  complemented  and  updated  during  TB  cases
ollow-up.  Patients  notified  in  the  database  are  diagnosed
ased  on  laboratory  confirmed  TB  (through  identification  of
.  tuberculosis  by  microscopy,  cultural  and/or  molecular
ethods)  and/or  based  on  clinical  and  radiological  findings
nd  a  favorable  TB  treatment  response.
For  this  study  ethics  committee  approval  or  informed
onsent  was  not  required,  as  all  patient’s  information
etrieved  from  the  SVIG-TB  database  was  fully  anonymized.
tudy  data
he  study  included  all  patients  notified  in  the  SVIG-TB
atabase  with  an  IGRA  test  result.  The  IGRA  test  used  in
he  patients  enrolled  in  the  study  was  the  QuantiFERON-TB
old  In-Tube  (Qiagen).
The  clinical  and  sociodemographic  variables  analyzed
ere  sex,  age  group,  comorbidities  (chronic  renal  failure2019.  https://doi.org/10.1016/j.pulmoe.2019.11.001
nfection,  chronic  obstructive  pulmonary  disease  [COPD]  and
iabetes),  substance  abuse  (alcohol  and  drug  abuse)  and
ite  of  disease  (pulmonary  or  extrapulmonary  TB).  IGRA  and
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Host  factors  associated  to  false  negative  and  indeterminate
TST  results  were  the  dependent  variable  (event:  negative
results).
Indeterminate  IGRA  results  were  assessed  by  dividing  the
results  into  determinate  (positive  and  negative  results)  and
indeterminate  (event).
Statistical  analysis
TST  induration  measurements  were  interpreted  using  two
cutoff  points,  ≥5  mm  (TST-5  mm)  and  ≥10  mm  (TST-10  mm),9
and  converted  to  positive  or  negative  results.
Results  from  patients  that  underwent  both  diagnostic
tests  were  used  to  calculate  the  sensitivity  with  95  %  confi-
dence  interval  for  each  test  separately  and  in  combination
(IGRA/TST-5  mm  or  IGRA/TST-10  mm).  Sensitivity  outcomes
were  compared  using  McNemar’s  test.10
Bivariate  and  multivariate  logistic  regression  analysis10
was  used  to  determine  the  variables  that  were  significan-
tly  associated  with  the  occurrence  of  indeterminate  and
false  negative  IGRA  results.  Multivariate  logistic  regression
analysis  with  forward  stepwise  (Likelihood  Ratio)  method,
logit  function  (entry-0.05;  removal-0.10),  included  variables
that  were  significant  in  bivariate  analyses.  Odds  ratio  were
reported  with  95  %  confidence  intervals  (95  %CI).  Statisti-
cal  analyses  were  performed  using  IBM® SPSS® Statistics  for
Windows,  version  23  (IBM  Corp.,  N.Y.,  USA).
Results
There  were  1230  patients  notified  with  active  TB  in  the  SVIG-
TB  database  (2008--2015)  with  an  IGRA  test,  857  patients
(69.7  %)  had  a  positive  test  result,  212  (17.2  %)  had  a neg-
ative  result  and  161  (13.1  %)  had  an  indeterminate  result.
Among  the  1069  patients  with  a  determinate  IGRA  result,
727  (68.0  %)  also  had  a  TST  result.
The  mean  (±standard  deviation)  age  of  the  patients
with  a  determinate  IGRA  result  (n  =  1069,  86.9  %)  was  47.9
(±20.0),  ranging  from  less  than  1  to  91  years.  Portugal  was
the  main  country  of  origin  (n  =  931;  87.1  %),  followed  by
Angola  (n  =  31,  2.9  %),  Cabo  Verde  (n  =  23,  2.2  %),  Guinea-
Bissau  (n  =  19,  1.8  %)  and  Mozambique  (n  =  12,  1.1  %).
Diabetes  mellitus  was  the  most  common  comorbidity  and
chronic  renal  failure  was  the  least  frequent.
IGRA  and  TST  sensitivity
Considering  the  patients  who  performed  IGRA  and  TST  assays
(n  =  727),  overall  sensitivity  was  82.4  %,  84.6  %  and  78.4  %
for  IGRA,  TST-5  mm  and  TST-10  mm,  correspondingly.  These
results  indicate  that  128  (17.6  %),  112  (15.4  %)  and  157  (21.6
%)  patients  with  a  diagnosis  of  active  TB  had  a  false  negative
result  with  IGRA,  TST-5  mm  and  TST-10  mm  tests,  respec-
tively.  Table  1  presents  the  sensitivity  results  for  IGRA  and
TST  for  total  of  patients  and  stratified  by  sociodemographic
and  clinical  variables.
Comparing  the  sensitivity  of  the  tests  separately  withPlease  cite  this  article  in  press  as:  Santos  JA,  et  al.  Pulmonol.  
the  combined  sensitivity  of  IGRA/TST-5  mm  and  IGRA/TST-
10  mm  (91.7  %  and  90.6  %,  respectively),  the  latter  was
consistently  higher  and  this  difference  was  statistically  sig-
nificant  (p  <  0.001)  --  Fig.  1.
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isk  factors  for  IGRA  indeterminate  results
f  the  161  patients  with  an  indeterminate  result,  the  major-
ty  were  male  (67.7  %)  with  a mean  age  of  56.0  (±19.4)  that
anged  from  5  to  92  years,  and  more  than  half  were  ≥50
ears  old  (57.1  %).
The  proportion  of  indeterminate  results  increases  as  the
ge  increases,  with  patients  over  80  years  old  presenting
he  highest  proportion  of  indeterminate  results  (34.5  %)  and
atients  under  20  years  old  presenting  the  lowest  proportion
f  indeterminate  results  (2.9  %).
Being  older  than  70  years,  alcohol  abuse  and  pulmonary
B  were  independent  predictive  factors  with  a  statistically
ignificant  association  to  higher  probability  of  indeterminate
GRA  results  in  TB  patients  (Table  2).
isk  factors  for  IGRA  false  negative  results
mong  the  risk  factors  analyzed  through  logistic  regression
Table  3),  two  presented  a  statistically  significant  associa-
ion  with  an  increased  risk  of  obtaining  false  negative  IGRA
esults  -  inflammatory  diseases  and  pulmonary  TB.
iscussion
he  objective  of  this  study  was  to  analyse  the  performance
f  an  IGRA  test  in  patients  with  active  TB  which  involved
stablishing  and  comparing  the  sensitivity  of  IGRA  and  TST
ests.
IGRA  sensitivity  results  are  heterogeneous  across  the  lit-
rature,  ranging  from  60  %11 to  nearly  100  %12 with  most
tudies  presenting  an  sensitivity  above  70  %,  as  demon-
trated  by  three  different  meta-analyzes  that  obtained  a
ooled  sensitivity  of  81.0  %,13 80.0  %14 and  84.2  %.15 In
ur  study,  IGRA  overall  sensitivity  (82.4  %)  was  close  to  the
ooled  sensitivity  of  these  meta-analyzes.  Nonetheless,  17.6
 of  the  results  were  false  negative,  demonstrating  that
lthough  these  tests  can  facilitate  diagnostic  decisions,  neg-
tive  results  should  not  be  used  alone  to  exclude  an  M.
uberculosis  infection  but  interpreted  in  conjunction  with
ther  clinical  findings  and  diagnoses.
Our  TST  sensitivity  was  higher  than  the  pooled  sensitiv-
ty  obtained  in  three  different  meta-analysis  -  66  %,15 70  %13
nd  77  %16 -  but  comparable  to  a  US  TB  surveillance  study
hat  included  almost  65  000  culture-confirmed  TB  patients,
n  which  84.2  %  of  the  patients  had  a  TST≥5 mm  and  81.6
 a  TST  ≥  10  mm.17 Despite  the  differences  in  sensitivity
btained  between  IGRA  and  TST-5  mm  or  TST-10  mm,  only
he  difference  between  IGRA  and  TST-10  mm  was  statisti-
ally  significant  (p  =  0.021),  which  indicates  that  IGRA  and
ST-5  mm  had  an  similar  performance  in  the  identification
f  cases  of  infection  and  presented  a  better  performance
han  TST-10  mm.
By  combining  the  results  of  the  two  tests,  the  sensitivity
ncreased  to  more  than  90.0  %,  and  the  difference  between
hese  results  and  those  obtained  by  the  tests  separately  was
tatistically  significant  (p  <  0.001).  Choi  et  al.  presented  sim-2019.  https://doi.org/10.1016/j.pulmoe.2019.11.001
lar  sensitivity  results,  obtaining  85.3  %  (TST),  70.3  %  (IGRA)
nd  93.3  %  (IGRA/TST).4 This  increase  in  sensitivity  suggests
hat  the  combined  use  of  the  two  tests  could  promote  the
dentification  of  more  cases  of  infection  than  if  used  sepa-
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Table  1  IGRA  and  TST  sensitivity  (5  mm  and  10  mm  cut-offs)  according  to  sex,  age  group,  comorbidities  (chronic  renal  failure,  oncologic  disease,  inflammatory  disease,  HIV,
diabetes and  COPD),  substance  abuse  (alcohol  or  drug  abuse)  and  site  of  disease  (pulmonary  or  extrapulmonary)  in  patients  submitted  to  both  assays  (n  =  727).
Variables Patients  IGRA  TST  -  5  mm  TST  -  10  mm
n/N  (%)  Positive  (n)  Sensitivity  %  (IC  95%)  Positive  (n)  Sensitivity  %  (IC  95%)  Positive  (n)  Sensitivity  %  (IC  95%)
Total  727  599  82.4  (79.5--84.9)  615  84.6  (82.0--87.2)  570  78.4  (75.4--81.4)
Sex Male 362/727  (49.8)  304  84.0  (79.9--87.4)  311  85.2  (81.6--88.8)  292  91.2  (88.3--94.1)
Female 365/727  (50.2)  295  80.8  (76.5--84.5)  304  84.0  (80.2--87.8)  278  92.3  (89.5--95.0)
Age group ≤15  48/727  (6.6)  37  77.1  (63.5--86.7)  35  72.9  (60.3--85.5)  31  85.4  (75.4--95.4)
16 --  64  523/727  (71.9)  431  82.4  (78.9--85.4)  458  87.6  (84.7--90.4)  423  92.5  (90.3--95.0)
≥ 65  156/727  (21.5)  131  84.0  (77.4--88.9)  122  78.2  (71.7--84.7)  116  91.0  (86.5--95.5)
Comorbidities Chronic renal  failure  5/727  (0.7)  4  80.0  (37.6--96.4)  3  60.0  (14.7--94.7)  3  80.0  (28.4--99.5)
Oncologic diseases  36/727  (5.0)  23  63.9  (47.6--77.5)  23  63.9  (48.2--79.6)  20  72.2  (57.6--86.9)
Inflammatory diseases  32/727  (4.4)  20  62.5  (45.3--77.1)  24  75.0  (60.0--90.0)  21  75.0  (60.0--90.0)
HIV infection  25/632  (3.4)  18  72.0  (52.4--85.7)  16  64.0  (44.5--79.8)  15  76.0  (56.6--88.5)
Diabetes 41/727  (5.6)  32  78.0  (63.3--88.0)  31  75.6  (62.5--88.8)  27  80.5  (68.4--92.6)
COPD 16/727  (2.2)  15  93.8  (71.7--98.9)  16  100  (79.4--100)  15  100  (79.4--100)
Substance abuse Alcohol  abuse  31/706  (4.3)  28  90.3  (75.1--96.7)  27  87.1  (75.3--98.9)  25  93.5  (78.6--99.2)
Drug abuse  32/709  (4.4)  27  84.4  (68.3--93.1)  31  96.9  (83.8--99.9)  31  100  (89.1--100)
Site of  disease PTB  343/727  (47.2)  275  80.2  (75.6--84.1)  292  85.1  (81.4--88.9)  270  91.5  (88.6--94.5)
ETB 384/727  (52.8)  324  84.4  (80.4--87.7)  323  84.1  (80.5--87.8)  300  91.9  (89.2--94.7)
PTB = Pulmonary tuberculosis; ETB = Extrapulmonary tuberculosis.
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Figure  1  Sensitivity  of  IGRA  and  TST  when  used  separately  and  when  used  together  (IGRA/TST-5  mm  and  IGRA/TST-10  mm)  in
patients with  both  test  results  (n  =  727).  Sensitivity  was  assessed  according  to  sex,  age  group  (≤15,  16-64,  ≥65  years),  comorbidities
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a(chronic renal  failure  [CRF],  oncologic  disease,  inflammatory  di
or drug  abuse)  and  site  of  disease  (pulmonary  TB  [PTB]  or  extra
rately  and  in  substitution  of  one  another.  The  combined  use
could  enhance  the  detection  of  LTBI  cases  among  vulnera-
ble  populations,18 such  as  homeless  people,  drug  or  alcohol
abusers,  prisoners  and  people  living  with  HIV.  This  approach
could  be  especially  helpful  in  low-incidence  countries,  as  the
majority  of  TB  cases  occur  due  to  the  progression  from  LTBI
to  TB  disease.19 Furthermore,  these  vulnerable  populations
are  frequently  associated  with  individual  and  contextual  fac-
tors,  as  presented  by  Zão  et  al,20 that  contribute  to  patient
and  healthcare  system  delay  in  the  diagnosis  and  treatment
of  TB.  A  false  negative  result  could  contribute  to  longer
delays,  thus  perpetuating  the  spread  of  the  disease.
Indeterminate  results  represent  a  considerable  problem
for  clinical  management,  since  they  imply  the  lack  of  clear
information  about  the  patient’s  TB  infection  status.
Unlike  other  studies,21,22 our  results  do  not  show  old  age
as  a  risk  factor  for  false  negative  IGRA  results.  However,  we
observed  that  older  age  was  a  predictive  factor  for  inde-
terminate  results,  which  was  consistent  with  the  findings  of
other  studies.21,23 Several  studies  analyzed  the  association
between  age  and  indeterminate  IGRA  results  and  concluded
that  indeterminate  results  are  significantly  more  common
in  children23--25 and  adolescents23 and  in  the  elderly.23,26 Our
results  confirm  part  of  their  conclusions,  with  patients  aged
>80  years  being  seven  times  more  likely  to  have  an  indeter-
minate  IGRA  result.  In  addition,  when  we  stratified  patients
in  ten-year  age  groups,  we  observed  that  the  proportion  of
indeterminate  results  increased  as  the  age  increases,  withPlease  cite  this  article  in  press  as:  Santos  JA,  et  al.  Pulmonol.  
patients  over  80  years  old  presenting  the  highest  proportion
of  indeterminate  results,  results  shared  with  Kobashi  et  al.26
In  our  study  younger  patients  did  not  present  any  association
with  false  negative  or  indeterminate  IGRA  results.
f
T
p
m,  HIV  infection,  diabetes  and  COPD),  substance  abuse  (alcohol
onary  TB  [ETB]).
Our  study  also  found  an  association  between  alcohol
buse  and  indeterminate  IGRA  results  in  which  patients  with
n  alcohol  problem  were  four  times  more  likely  to  have  an
ndeterminate  outcome.  Both  acute  and  chronic  alcohol  use
ave  profound  regulatory  effects  on  the  immune  system,27
hich  possibly  impairs  the  patient’s  ability  to  respond  cor-
ectly  to  the  IGRA,  resulting  in  an  indeterminate  result.
ecause  alcohol  dependence  was  based  on  self-report  and
aily  alcohol  intake  was  not  determined,  further  studies
ith  a  more  detailed  information  on  alcohol  consumption
re  needed  to  better  understand  this  potential  association.
From  the  studies  available  involving  IGRA,  PTB  patients
nd  ETB  patients,  the  test  sensitivity  remains  similar  in  both
orms  of  TB,  as  shown  by  Di  et  al.28 (89.7  %  vs  79.7  %),  Ji
t  al.29 (89.7  %  vs  87.6  %),  Azghay  et  al.30 (78.9  %  vs  87.8  %)
nd  in  our  study  (80.2  %  vs  84.4  %).  However,  pulmonary  TB
as  presented  as  a  predictive  factor  for  indeterminate  and
alse  negative  results,  in  which  these  patients  were  almost
hree  times  more  likely  to  have  an  indeterminate  outcome
nd  nearly  twice  as  likely  to  have  a  false  negative  result
ompared  to  extrapulmonary  TB  (ETB)  patients.
Clinical  manifestations  of  ETB  may  vary  from  an  acute  or
isseminated  disease,  such  as  meningitis  or  miliary  TB,  to  a
hronic  localized  infection  with  an  insidious  onset  and  slow
rogression,  such  as  lymph  node  or  osteoarticular  TB.31,32 In
wo  analyses  of  risk  factors  of  false-negative  IGRA  results,
nly  meningitis  TB  from  the  eight  forms  of  ETB  in  one  study
nd  6  forms  in  the  other  was  significantly  associated  with2019.  https://doi.org/10.1016/j.pulmoe.2019.11.001
alse  negative  results,  an  acute  clinical  manifestation.28,33
hus,  the  fact  that  most  ETB  manifestations  have  a  slower
rogression  to  severe  disease,  possibly  allows  patients  to
aintain  a  functional  immune  system  and  consequently
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Table  2  Sociodemographic  and  clinical  characteristics  of  161  patients  with  indeterminate  IGRA  results  and  their  association  with  the  occurrence  of  the  indeterminate  test
results in  patients  with  active  TB.
Variables
(reference  class)
Indeterminate  IGRA  Crude  Odds  Ratio  Adjusted  Odds  ratio  (by  sex  and  age)  Final  Model  (FR)
n  (%)  OR  (95  %CI)  p  OR  (95  %CI)  p  OR  (95  %CI)  P
Sex  (Female)  Male  109  (67.7)  1.94  (1.37--2.76)  <0.001  1.95  (1.37--2.8)  <0.001
Age
group
(41--50)
<10 1  (0.6)  0.23  (0.03--1.75)  0.155  0.23  (0.03--1.79)  0.161
11-20 2  (1.2)  0.24  (0.06--1.05)  0.059  0.23  (0.05--1.01)  0.061
21-30 12  (7.5)  0.83  (0.40--1.71)  0.616  0.88  (0.43--1.82)  0.735
31-40 28  (17.4)  1.36  (0.77--2.40)  0.296  1.41  (0.79--2.49)  0.246
51-60 26  (16.1)  1.10  (0.59--2.03)  0.753  1.11  (0.60--2.05)  0.741
61-70 21  (13.0)  1.26  (0.63--2.12)  0.639  1.23  (0.67--2.26)  0.508
71 -  80  30  (18.6)  1.79  (1.01--3.15)  0.045  1.83  (1.03--3.24)  0.039  2.52  (1.16--5.48)  0.020
> 80  19  (11.8)  4.24  (2.13--8.45)  <0.001  4.21  (2.1--8.44)  <0.001  7.22  (2.83-18.4)  <0.001
Comorbidities (No) Chronic  renal  failure  1  (0.6)  0.51  (0.07--3.91)  0.515  0.34  (0.04--2.76)  0.313
Oncologic  diseases  13  (8.1)  1.45  (0.78--2.71)  0.241  1.06  (0.55--2.03)  0.873
Inflammatory  diseases  5  (3.1)  0.67  (0.26--1.70)  0.397  0.63  (0.24--1.64)  0.340
HIV infection  14  (8.7)  1.79  (0.97--3.33)  0.061  1.76  (0.91--3.4)  0.092
Diabetes  16  (9.9)  1.79  (1.01--3.19)  0.047  1.59  (0.87--2.95)  0.134
COPD 9  (5.6)  2.69  (1.22--5.93)  0.014  1.81  (0.79--4.15)  0.159
Substance abuse
(No)
Alcohol  abuse  27  (16.8)  4.15  (2.52--6.83)  <0.001  4.07  (2.36--7.01)  <0.001  4.17  (2.23--7.81)  <0.001
Drug abuse  15  (9.3)  2.52  (1.37--4.64)  0.003  2.75  (1.41--5.35)  0.003
Site of  disease  (ETB)  PTB  116  (72.0)/45  (28.0)  3.15  (2.19--4.54)  <0.001  3.544  (2.43--5.18)  <0.001  2.85  (1.79--4.53)  <0.001
OR = Odds ratio; CI = confidence interval; PTB = Pulmonary tuberculosis; ETB = Extrapulmonary tuberculosis. FR - Forward stepwise (LR).
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Table  3  Association  between  false  negative  IGRA  results  and  sociodemographic  and  clinical  variables  among  patients  with  notified  TB  (n  =  1069).
Variables
(reference  class)
Patients Crude  Odds  Ratio Adjusted  Odds  ratio  (by  sex  and  age) Final  Model  (FR)
n/N  (%) OR  (95  %CI) p  OR  (95  %CI) p  OR  (95  %CI) p
Sex  (Female) Male  555/1069  (51.9) 0.87  (0.64--1.17) 0.352  0.86  (0.63--1.16) 0.325
Age
group
(41--50)
<10 35/1069  (3.3) 1.34  (0.60--2.99) 0.472  1.34  (0.60--2.98) 0.476
11-20 66/1069  (6.2) 0.75  (0.37--1.51) 0.413  0.75  (0.37--1.52) 0.428
21-30 116/1069  (10.9) 0.97  (0.56--1.67) 0.909  0.96  (0.55--1.65) 0.872
31-40 166/1069  (15.5) 0.83  (0.51--1.37) 0.471  0.82  (0.49--1.36) 0.445
51-60 209/1069  (19.6) 0.62  (0.36--1.07) 0.088  0.62  (0.36--1.07) 0.084
61-70 153/1069  (14.3) 0.66  (0.38--1.12) 0.122  0.65  (0.38--1.11) 0.111
71 -  80 153/1069  (14.3) 0.84  (0.49--1.43) 0.516  0.83  (0.49--1.41) 0.493
> 80  135/1069  (12.6)  0.81  (0.33--1.96)  0.64  0.82  (0.34--1.99)  0.66
Comorbidities  (No) Chronic  renal  failure  13/1069  (1.2)  0.73  (0.16-3.33)  0.687  0.85  (0.18-3.92)  0.835
Oncologic diseases  61/1069  (5.7)  1.611  (0.90--2.88)  0.108  1.64  (0.90--2.97)  0.105
Inflammatory  diseases  49/1069  (4.6)  2.25  (1.22--4.13)  0.009  2.40  (1.29--4.46)  0.006  2.04  (1.04--4.01)  0.039
HIV infection  59/931  (5.5)  1.22  (0.66--2.28)  0.528  1.18  (0.62--2.24)  0.62
Diabetes 62/1069  (5.8)  0.77  (0.38--1.53)  0.452  0.89  (0.44--1.84)  0.767
COPD 23/1069  (2.2)  0.85  (0.29--2.52)  0.767  0.93  (0.31--2.79)  0.892
Substance abuse
(No)
Alcohol  abuse  57/1029  (5.3)  0.65  (0.30-1.39)  0.263  0.69  (0.32-1.53)  0.371
Drug abuse  47/1042  (4.4)  0.96  (0.46--2.01)  0.904  0.93  (0.43--2.0)  0.85
Site of  disease  (ETB) PTB  481/1069  (45.0)  1.71  (1.26--2.31)  0.001  1.67  (1.22--2.29)  0.001  1.69  (1.22--2.35)  0.002
OR = Odds ratio; CI = confidence interval; PTB = Pulmonary tuberculosis; ETB = Extrapulmonary tuberculosis.
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unctional  T-cells  which,  when  presented  with  TB  antigens,
ill  respond  with  the  production  of  interferon-. Another
eason  for  these  results  may  lie  in  the  severity  of  pulmonary
B  cases.  Different  studies  have  shown  that  severe  pul-
onary  disease  can  be  associated  with  immune  suppression
hich  may  lead  to  reduced  interferon- production.34,35 Dur-
ng  TB  progression,  the  natural  cytokine  balance  is  altered
hile  the  bacterial  load  increases,  potentially  influencing
he  performance  of  IGRA  tests  resulting  in  a  reduction
n  M.  tuberculosis  specific  immune  responses,  especially
nterferon- production.36,37
Considering  the  existence  of  highly  heterogeneous  clin-
cal  manifestations  associated  to  the  fact  that  most  forms
f  ETB  do  not  contribute  to  the  transmission  of  TB,  and  also
onsidering  that  research  in  ETB  and  their  influence  in  the
mmune  response  is  scarce,  it  is  imperative  to  develop  fur-
her  studies  in  order  to  better  understand  the  performance
f  the  test  in  the  different  clinical  manifestations  of  TB.
We  observed  that  inflammatory  diseases  were  an  inde-
endent  predictive  factor  for  negative  IGRA  results  in
atients  with  active  TB.  With  the  growing  use  of  bio-
ogic  therapies  for  inflammatory  rheumatic  diseases  and  the
ncreased  risk  of  TB  associated38 with  their  use,  our  results
how  that  the  use  of  IGRA  alone  may  not  be  sufficient  to
liminate  the  possibility  of  an  M.  tuberculosis  infection.  In
iew  of  the  high  risk  of  TB  in  these  patients  and  the  pos-
ibility  of  false  negative  results,  a  dual  testing  strategy  of
GRA  and  TST  could  be  more  effective  for  LTBI  diagnosis,  as
ther  studies  involving  patients  with  inflammatory  diseases
oncluded.39--41
In  our  study,  five  of  the  49  patients  with  inflammatory
iseases  presented  an  indeterminate  IGRA  result  but  no  sig-
ificant  association  was  found.  Some  studies  have  identified
n  association,39,42,43 with  the  corticosteroids  used  in  the
reatment  of  these  diseases  being  the  common  predictive
actor  for  indeterminate  results.  No  treatment  data  was
vailable  in  our  study.
Our  study  has  limitations.  T-cell  assays  like  IGRA  are  sus-
eptible  to  variability  by  different  factors  associated  with
ssay  manufacturing,  pre-analytical  processing  or  analytical
esting.3 However,  despite  their  importance  we  were  unable
o  determine  the  impact  of  these  factors  on  the  IGRA  results
sed  in  the  study.  Due  to  the  absence  of  healthy  individu-
ls  in  our  study  population,  it  was  not  possible  to  estimate
he  specificity  for  both  immunologic  tests,  TST  and  IGRA.
he  presence  of  variables  based  on  patient  self-report  (e.g.
lcohol  abuse,  drug  abuse)  may  have  led  to  a  less  accu-
ate  estimate  of  the  impact  of  these  variables.  The  use  of
ctive  TB  patients  as  a  proxy  to  assess  the  sensitivity  of  IGRA
nd  TST  has  the  disadvantage  that  patients  with  active  TB
ay  present  immunosuppression  due  to  the  disease  itself,
hus  obtaining  a  different  response  than  with  patients  with
 latent  infection  or  recent  infection.
On  the  other  hand,  our  analysis  of  the  performance  of
he  IGRA  test  was  comprehensive.  It  involved  a  consider-
ble  number  of  patients  with  different  risk  factors,  which
llowed  observation  of  the  performance  of  IGRA  in  different
ontexts,  contributing  to  a  better  understanding  of  how  toPlease  cite  this  article  in  press  as:  Santos  JA,  et  al.  Pulmonol.  
se  this  test  in  populations  with  certain  risk  factors.  In  addi-
ion,  the  comparison  with  the  other  screening  method  for
TBI  available  (TST)  provided  additional  information  on  how PRESS
J.A.  Santos  et  al.
hese  tests  can  be  used  in  order  to  enhance  the  detection
f  cases  of  infection.
onclusion
n  our  study  we  identified  three  factors  associated  with  the
ccurrence  of  indetermined  IGRA  results  -  age  over  70  years,
lcohol  abuse  and  pulmonary  TB.
Inflammatory  diseases  and  pulmonary  TB  were  indepen-
ent  risk  factors  for  false  negative  IGRA  results  in  patients
ith  active  TB.
Given  the  impact  that  treatments  of  inflammatory  dis-
ases  have  on  the  development  of  active  TB,  our  results
uggest  a  careful  interpretation  of  a  negative  result,  since
here  is  a  significant  risk  of  false  negative  results.
The  fact  that  the  IGRA  appears  to  perform  well  in  patients
ith  ETB  (less  indeterminate  and  false  negative  results  than
n  patients  with  pulmonary  TB),  makes  it  a  valuable  diag-
ostic  tool  in  these  cases.
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